Karen Flynn
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Quanterix Highlights Spatial Biology Innovation at ESSB 2026. Quanterix announced it met its spatial biology content innovation commitments during the ESSB 2026 event. The company showcased new tools and data sets that support advanced spatial analysis. This demonstrates progress in its product roadmap and may strengthen its position in the spatial biology market.
Transaction History
| STVN | ▼ Sell | Open Market | 1,493 | $26K | 6/15/2026 | View on chart |
| STVN | ▲ Buy | Grant | 4,975 | $0 | 6/12/2026 | View on chart |
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| QTRX | ▲ Buy | Grant | 23,372 | $0 | 1/2/2026 | View on chart |
| SHC | ▲ Buy | Grant | 19,132 | $0 | 5/22/2025 | View on chart |
| QTRX | ▲ Buy | Grant | 7,435 | $0 | 1/2/2025 | View on chart |
| SHC | ▲ Buy | Grant | 20,089 | $0 | 5/24/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 2,947 | $0 | 1/2/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 8,083 | $0 | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 918 | $12K | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,066 | $11K | 10/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 164 | $3K | 7/1/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 13,227 | $0 | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Stevanato Group joins Ensera alliance with medical device partners
Stevanato Group has joined a new alliance network led by Ensera, alongside partners like SHL Medical and Ypsomed. This move aims to strengthen collaboration within the medical device supply chain. The stock is currently trading near its support level, with an average analyst target of $24.68.
Stevanato Group joins Ensera alliance with medical device partners. Stevanato Group has joined a new alliance network led by Ensera, alongside partners like SHL Medical and Ypsomed. This move aims to strengthen collaboration within the medical device supply chain. The stock is currently trading near its support level, with an average analyst target of $24.68.